Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma

Veterinary and Comparative Oncology

Volumn 8, Issue 1, 2010, Pages 11-22

  Daters, A T ^a   Mauldin, G E ^a   Mauldin, G N ^a   Brodsky, E M ^b   Post, G S ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b Veterinary Oncology and Hematology Center   (United States)

Author keywords

Canine; Chemotherapy; Mitoxantrone; Multicentric lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; DOG; DOG DISEASE; FEMALE; LYMPHOMA; MALE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CYCLOPHOSPHAMIDE; DOG DISEASES; DOGS; DOXORUBICIN; FEMALE; LYMPHOMA; MALE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

CANIS FAMILIARIS;

EID: 75249102685     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2009.00199.x     Document Type: Article

References (28)

1. Kaiser HE, Kaiser HE. Animal neoplasms: a systemic review. Neoplasms-Comparative Pathology in Animals, Plants and Man 1981, 747-812. In:, ed.,, Baltimore, Williams and Wilkins
2. Jacobs RM, Messick JB, Valli VE, Meuten DJ. Tumors of the hemolymphatic system. Tumors of Domestic Animals 2002, In:, 4th edn., ed.,, Iowa, State Press, 138.
3. Dorn CR, Taylor DO, Frye FL, Hibbard HH. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. I. Methodology and description of cases. Journal of the National Cancer Institute 1968, 40:295-305.
4. Vail DM, Young KM, Withrow SJ, Vail DM, Philadelphia WB. Canine lymphoma and lymphoid leukemias. Withrow and MacEwen's Small Animal Clinical Oncology 2001, 699-733. In:, 4th edn., Saunders,
5. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. Journal of Veterinary Internal Medicine 1993, 7:289-295.
6. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002, 16:704-709.
7. Mauldin GE, Fox PR, Patnaik AK, Bond BR, Mooney SC, Matus RE. Doxorubicin-induced cardiotoxicosis. Clinical features in 32 dogs. Journal of Veterinary Internal Medicine 1992, 6:82-88.
8. Doroshow JH, Chabner BA, Longo DL. Anthracyclines and anthracenediones. Cancer Chemotherapy and Biotherapy, Principles and Practice 2006, 414-450. In:, 4th edn., eds.,, Philadelphia, Lippincott Williams and Wilkins,
9. Lucroy MD, Phillips BS, Kraegel SA, Simonson ER, Madewell BR. Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma. Journal of Veterinary Internal Medicine 1998, 12:325-329.
10. Moore AS, Ogilvie GK, Ruslander D, Rand WS, Cotter SM, Getzy DM, L'Heureux DA, Dennis RA. Evaluation of mitoxantrone for the treatment of lymphoma in dogs. Journal of the American Veterinary Medical Association 1994, 204:1903-1905.
11. Ogilvie GK, Obradovich JE, Elmslie RE, Vail DM, Moore AS, Straw RC, Dickinson K, Cooper MF, Withrow SJ. Efficacy of mitoxantrone against various neoplasms in dogs. Journal of the American Veterinary Medical Association 1991, 198:1618-1621.
12. Carpenter LG, Withrow SJ, Powers BE. Squamous cell carcinoma of the tongue in 10 dogs. Journal of the American Animal Hospital Association 1993, 29:17-24.
13. Owen LN. TNM Classification of Tumors of Domestic Animals 1980, 46-47. 1st edn., Geneva, World Health Organization,
14. Common terminology criteria for adverse effects (VCOG-CTCAE) following chemotherapy or biological anti-neoplastic therapy in dogs and cats v1.0. Veterinary Comparative Oncology 2004, 2:194-213. Veterinary Co-operative Oncology Group
15. LeBlanc AK, Mauldin GE, Milner RJ, LaDue TA, Mauldin GN, Bartges JW. Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. Veterinary and Comparative Oncology 2006, 4:21-32.
16. Fidler JM, DeJoy SQ, Gibbons JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. Journal of Immunology 1986, 137:727-732.
17. Weilbach FX, Chan A, Toyka KV, Gold R. Mitoxantrone-induced immunological changes in MS patients-ex vivo studies on proliferation and cell death of peripheral blood leukocytes. Journal of Neurology 2002, 1:113.
18. Bellosillo B, Colomer D, Pons G, Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. British Journal of Haematology 1998, 100:142-146.
19. Chun R, Garrett LD, Vail DM. Evaluation of a high dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2000, 14:120-124.
20. Moore AS, Cotter SM, Rand WM, Wood CA, Williams LE, London CA, Frimberger AE, L'Heureux DA. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. Journal of Veterinary Internal Medicine 2001, 348-354.
21. Simon D, Nolte I, Eberle N, Abbrederis N, Killich M, Hirschberger J. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. Journal of Veterinary Internal Medicine 2006, 20:948-954.
22. Alvarez FJ, Kisseberth WC, Gallant SL, Couto CG. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma. Journal of Veterinary Internal Medicine 2006, 20:1178-1183.
23. Rassnick KM, Mauldin GE, Al-Sarraf R, Mauldin GN, Moore AS, Mooney SC. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000). Journal of Veterinary Internal Medicine 2002, 16:576-580.
24. Hosoya K, Kisseberth WC, Lord LK, Alvarez FJ, Lara-Garcia A, Kosarek CE, London CA, Couto CG. Comparison of COAP and UW-19 Protocols for dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine 2007, 21:1355-1363.
25. Rassnick KM, McEntee MC, Erb HN, Burke BP, Balkman CE, Flory AB, Kiselow MA, Autio K, Geiger TL. Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma. Journal of Veterinary Internal Medicine 2007, 21:1364-1373.
26. Sauerbrey ML, Mullins MN, Bannink EO, Van Dorp TER, Kaneene JB, Obradovich JE. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). Journal of the American Veterinary Medical Association 2007, 230:1866-1869.
27. MacDonald VS, Thamm DH, Kurzman ID, Turek MM, Vail DM. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? Journal of Veterinary Internal Medicine 2005, 19:732-736.
28. Mauldin GN, Truax R. Evaluation of the in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles. Veterinary Therapeutics 2002, 3:290-296.